Cytokinetics (CYTK) Net Margin (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Net Margin of 956.87% for Q1 2026, up 951038.0% year-over-year from N/an in Q1 2025, and up 3.45% quarter-over-quarter from 991.05% in Q4 2025.
Powered by 
Analysis
Cytokinetics (CYTK) Net Margin (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Net Margin for 17 consecutive years, with 956.87% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin rose 951038.0% year-over-year to 956.87%; the TTM figure through Mar 2026 stood at 635.68% (up 287175.0% YoY), while the FY2025 annual figure was 1042.33%, up 728537.0% from the prior year.
- Net Margin improved to 956.87% in Q1 2026 per CYTK's latest filing, from 991.05% in the prior quarter.
- Across five years, Net Margin topped out at 15.38% in Q2 2022 and bottomed at 57391.16% in Q2 2024.
- Historically, Net Margin has averaged 12206.53% across 5 years, with a median of 7199.23% in 2022.
- Annual changes were most pronounced in 2024 — Net Margin plunged 4250143 bps — and 2025, when it soared 5720756 bps.
- Cytokinetics' Net Margin stood at 7199.23% in 2022, then increased by 3 bps to 6971.95% in 2023, then surged by 86 bps to 990.39% in 2024, then slipped by 0 bps to 991.05% in 2025, then grew by 3 bps to 956.87% in 2026.
- Business Quant data shows CYTK's Net Margin at 956.87% in Q1 2026, 991.05% in Q4 2025, and 9756.87% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Cytokinetics | 9.63 Bn | 8.46 Bn | 25.89 Mn | -625.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -625.95% |
| Mar 31, 2026 | -948.69% |
| Dec 31, 2025 | -1,084.99% |
| Sep 30, 2025 | -9,199.79% |
| Jun 30, 2025 | -183.60% |
| Mar 31, 2025 | -9,856.30% |
| Dec 31, 2024 | -986.52% |
| Sep 30, 2024 | -32,338.88% |
| Jun 30, 2024 | -57,391.16% |
| Mar 31, 2024 | -15,968.62% |
| Dec 31, 2023 | -8,049.16% |
| Sep 30, 2023 | -34,233.07% |
| Jun 30, 2023 | -14,889.73% |
| Mar 31, 2023 | -2,849.21% |
| Dec 31, 2022 | -6,851.66% |
| Sep 30, 2022 | -4,582.31% |
| Jun 30, 2022 | -15.38% |
| Mar 31, 2022 | -7,353.75% |
| Dec 31, 2021 | -46.62% |
| Sep 30, 2021 | -1,349.31% |